Asciminib vs bosutinib in CML patients pretreated with ≥2 tyrosine kinase inhibitors: Results from the Japanese subgroup analysis of ASCEMBL study

Asciminib, a first‐in‐class, allosteric inhibitor of BCR‐ABL1 that acts by STAMP (Specifically Targeting the ABL Myristoyl Pocket), is a novel therapeutic option for patients with chronic myeloid leukemia (CML). In the global, phase 3, open‐label ASCEMBL study in patients with CML in chronic phase (...

Descripción completa

Detalles Bibliográficos
Autores principales: Yuda, Junichiro, Doki, Noriko, Matsuoka, Hiroshi, Yokota, Takafumi, Tomita, Akihiro, Takahashi, Naoto, Matsumura, Itaru, Kubo, Kohmei, Goto, Tatsunori, Kirito, Keita, Maki, Akio, Aoki, Makoto, Allepuz, Alex, Minami, Yosuke
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2022
Materias:
RESEARCH ARTICLES
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9939084/
https://www.ncbi.nlm.nih.gov/pubmed/36168187
http://dx.doi.org/10.1002/cam4.5212

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9939084/
https://www.ncbi.nlm.nih.gov/pubmed/36168187
http://dx.doi.org/10.1002/cam4.5212

Ejemplares similares